Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Applies Unique Database to Improve Cancer Outcomes

Predictive Oncology (NASDAQ: POAI), through its Helomics subsidiary, is leveraging its proprietary database of more than 150,000 tumor genomic and drug response profiles to improve cancer outcomes. An article discussing the company reads, “With a mission to improve the standard of care for cancer patients, Helomics’ TruTumor(TM) platform harnesses the power of the patient’s own living tumor to address challenges oncologists often face when assessing patients and individualizing treatments. The clinically validated (in ovarian cancer) cell-based functional platform is in use today and profiles patient tumors, identifying key biomarkers and how the tumor responds to drugs and helps the oncologist determine a tailored therapy for that patient. . . . Helomics’ is building AI-driven predictive models by leveraging a unique database of 150,000 tumor genomic and drug response profiles gathered from over 15 years of clinical testing using its TruTumor platform, access to over 15 years of outcome data from a national network of oncologists, plus a physical biobank of tumor samples that is being sequenced as part of its CancerQuest 2020 initiative (http://ibn.fm/B9mmE) to generate rich genomic profiles.”

To view the full article, visit http://ibn.fm/tokKQ

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other) that contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient-treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled with a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform Kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) Subsidiary Providing Premium Medical Teleconferences

Trxade Group (NASDAQ: MEDS), through its virtual healthcare subsidiary Bonum Health, provides telehealth services and prescription ordering via teleconferences that are conducted using smart devices. A recent article discussing the company reads, “The service provides subscribers with three premium medical teleconferencing visits through Bonum Health and prescription delivery through the company’s DelivMeds same day/mail-order pharmaceuticals service each month under the standard membership rate. . . . ‘With the seasonal flu outbreaks and the current coronavirus surge, patients are quick to brush off common symptoms, including cough, fever and body aches, as signs of a common cold; Telemedicine removes the barrier of self-doubt and complacency in the current climate of worldwide viral infections,’ the company stated in a news release (http://ibn.fm/BrWLY).”

To view the full article, visit http://ibn.fm/Hdbd8

About Trxade Group Inc.

Headquartered in Tampa, Florida, Trxade Group is an integrated drug-procurement, delivery and healthcare platform that enables price transparency and increased profit margins to buyers and sellers of pharmaceuticals, makes healthcare services affordable and accessible across all 50 states, and steps in to meet today’s immediate demands. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms: the Trxade B2B trading platform with 12,100 registered pharmacies, a licensed virtual wholesaler, affordable healthcare via its Bonum Health app or web-based telehealth services, and same-day or mail-order pharmacy-delivery capabilities via its DelivMeds app featuring its extensive nationwide distribution network. For additional information, please visit www.Trxade.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Trxade Group Inc. (MEDS) | Leave a comment

Sigma Labs Inc. (NASDAQ: SGLB) Stands to Benefit from Post-Epidemic Trends Aimed at Strengthening Manufacturing, Supply Chain

  • COVID-19 exposed weaknesses in manufacturing, supply chain spaces; 3D printing offers ideal solution
  • 3D-metal-printing presents its own mechanical hurdles, including quality issues undetected until postproduction
  • SGLB’s patented PrintRite3D(R) software provides solution to costly quality-control challenges that impede manufacture of precision 3D-metal parts

Among the many changes wrought by COVID-19, those within the manufacturing and supply chain sectors will likely be far reaching and long lasting. The epidemic has exposed fundamental weaknesses in the system, some of which may be solved through advanced software and technologies, including 3D metal printing. Sigma Labs Inc. (NASDAQ: SGLB), a leading developer of quality-assurance software in the commercial 3D-metal-printing space, may benefit from the trend.

“3D printing has come a long way in recent years, with manufacturing times improving,” a recent Forbes article reads (http://ibn.fm/OB0WW). “The time it takes to print items depends on both the quality of the printer as well as the complexity of the item being printed. As we enter a new era with COVID-19 continuing to disrupt supply chains and causing shortages of essential medical equipment, the 3D printing community is stepping in to help.”

Another article, published by MarketWatch, makes a similar observation. “Out of necessity, manufacturers in the new normal will build factories much closer to where critical parts are needed, reduce the human workforce, and rely more on software and efficiency technologies like 3D printing,” the article reads (http://ibn.fm/EfzTG). “At the epicenter of this sea of change is Sigma Labs, with its revolutionary patented technology that detects and identifies defects and anomalies in real time during the 3D printing process of metal, paving the way for scalability and economic efficiency.”

Both articles point out that additive manufacturing, or 3D printing, speeds production, allows flexibility, and brings new ideas to market quicker at lower cost. However, the new technology is not perfect. “Commercial 3D metal printing is gaining vital importance in the entire global manufacturing sector – yet the efficiency it yields is not without challenges,” the MarketWatch article notes. “A myriad of variables from machines to materials create production hurdles in metal additive manufacturing.”

Among those problems is the fact that the newly printed parts don’t always meet precise specifications. Previously, 3D-metal-printing manufacturers have had to rely on post-production inspection techniques to detect these imperfections, which are both costly and wasteful, since the problem isn’t discovered until the printing is complete, rendering the part unusable.

“With its patented PrintRite3D(R) software, Sigma Labs presents a solution to the costly quality-control challenges that impede the volume manufacture of precision 3D metal parts,” the article continues. “In doing so, Sigma’s software could easily become indispensable in the global efforts to meet the manufacturing challenges of post COVID. The company’s breakthrough software has the potential to bolster and broaden commercial metal-additive manufacturing by enabling for the first time cost-effective, nondestructive quality assurance during the production process. PrintRite3D(R) is the leading technology in identifying and classifying defects and anomalies in-process and allows for errors to be corrected in real time — even remotely.”

Sigma Labs Inc. is a leading provider of quality-assurance software to the commercial 3D-metal-printing industry under the PrintRite3D brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D for 3D-metal, advanced-manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real time during the manufacturing process and informs the production manager of quality issues. Sigma Labs’ software product is a major catalyst for the acceleration and adoption of 3D metal printing.

For more information about Sigma Labs, please visit www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Sigma Labs Inc. SGLB | Leave a comment

MissionIRNewsBreaks – Sigma Labs Inc. (NASDAQ: SGLB) Completes Management Transition Process with Appointment of CEO, President

Sigma Labs (NASDAQ: SGLB), a leading provider of in-process, quality-assurance software for the additive manufacturing industry, recently appointed experienced software industry executive Mark K. Ruport as CEO and president (http://ibn.fm/oNSOj). The move finalizes the company’s management transition process. An article further discussing the new appointment reads, “In his new assignment, Ruport will leverage his experience with public and private software companies to lead Sigma Labs through a period of significant growth and success. ‘The ability to have an immediate, tangible impact on Sigma Labs with the apparent adoption of its incredible technology in the marketplace is a unique and exciting opportunity,’ Ruport said in a news release announcing his December appointment. ‘My focus will be on accelerating our commercial adoption with strategic partners and amplifying the recent success John [Rice] and his team have achieved. This blueprint is something I am very familiar with given my experience with disruptive companies in the software sector, and I look forward to working with the entire team at Sigma Labs to drive forward its strategic initiatives.’”

To view the full article, visit http://ibn.fm/DscFj

About Sigma Labs Inc.

Sigma Labs is a leading provider of quality-assurance software to the commercial 3D-metal-printing industry under the PrintRite3D(R) brand. Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided inspection (“CAI”) solutions known as PrintRite3D for 3D advanced-manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, uniquely allowing errors to be corrected in real time. For more information, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Sigma Labs Inc. SGLB | Leave a comment

MissionIRNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Rebrands Investor Intelligence Platform

SRAX (NASDAQ: SRAX) recently announced the rebranding of its investor intelligence platform from SRAX IR to Sequire. An article further discussing the platform reads, “The investor-relations platform, which enables companies to monitor their shareholders’ buying and selling behavior and carry out virtual investor meetings among other services, announced that it had gained 59 corporate subscribers as of the end of 2019 — a remarkable 64% increase relative to the quarter ending Sept 30, 2019. . . . ‘We are thrilled to announce the new brand, giving the platform its own identity separate from SRAX,’ SRAX CEO and founder Christopher Miglino noted in a news release regarding the rebranding announcement (http://ibn.fm/tfKtt). ‘It’s also arriving at an opportune time as we are developing new intelligent technologies to further provide public companies the tools to reach and engage their shareholders.’”

To view the full article, visit http://ibn.fm/tZU7w

About SRAX

SRAX is a digital-marketing and consumer-data-management technology company. SRAX’s technology unlocks data for brands in the CPG, investor relations, luxury and lifestyle verticals. Through its various platforms, SRAX is monetizing its data sets and growing multiple recurring revenue streams. BIGtoken is a consumer-managed data marketplace where people can own and earn from their data. The platform also provides advertisers and media companies access to transparent, verified consumer data to better reach and serve audiences. Sequire is a premier platform for investor intelligence and communication. Through Sequire, public companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX and its verticals, visit www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, SRAX, Inc. SRAX | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Helomics Subsidiary Holds Unique Cancerous Tumor Inventory

Predictive Oncology (NASDAQ: POAI) CEO Dr. Carl Schwartz recently referred to the company’s Helomics subsidiary as a “major asset” during an exclusive NNW interview with Stuart Smith (http://ibn.fm/8knZX). An article discussing the interview reads, “During the interview, Schwartz pointed out that Helomics’ collection of more than 150,000 cancer tumors is the largest inventory of its kind in the world and that the impressive collection ‘was amassed over the last two decades by physicians sending in cancerous tumors to be tested with the known therapies of the time. The results of these tests were in turn sent back to the referring physicians to be used as a guide or a reference as desired for treatment of the evaluated tumor,’ he continued. ‘And the evaluated tumor was placed back in the physician’s therapy inventory. That’s how we amassed all these tumors.’ . . . Schwartz explained that POAI was intent on proving that it can sequence, ‘which is genetically profile our tumors, and do what is called a ‘reach back,’ or examination of what eventually happened to these patients over an extended period of time. I want to strongly emphasize that Helomics is the only company with the ability to do this ‘reach back’ at this time because only we have a patient history.’”

To view the full article, visit http://ibn.fm/ZoNgh

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other) that contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient-treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled with a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform Kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Secures $2.5 Million in Cash Proceeds from Recent Warrant Exercises

Genprex (NASDAQ: GNPX) today announced the exercise of warrants to purchase approximately 5.4 million shares of common stock issued in connection with capital raises in May 2018 and November 2019 with two institutional investors at a price of $0.46 per share, resulting in its receipt of approximately $2.5 million in cash proceeds. According to the update, the warrants were exercised on or about May 22, 2020, the first day they became exercisable under their respective agreement terms. The exercised warrants represent approximately 70% of the company’s overall outstanding warrants and include all warrants that have been issued to investors in the company’s public financings to date. After the exercise, remaining warrants carry a weighted average exercise price of approximately $3.93. Genprex believes the elimination of the majority of its outstanding warrants represents a significant milestone for the company, providing a dramatically simplified capital structure.

To view the full press release, visit http://ibn.fm/1QWNi

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, Oncoprex(TM), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). Oncoprex has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for Oncoprex immunogene therapy for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)). For more information, please visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Pressure BioSciences, Inc.’s (PBIO) Pending Partner Cannaworx to Launch FDA Registered, Hemp-Containing Supplements with Immune Booster Claim

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that its pending merger partner Cannaworx, Inc. will be launching its patented and proprietary immune booster supplement by mid-July 2020. According to the update, the company believes that post-launch, this product could be one of the very few, and perhaps the only, OTC (over the counter), FDA registered, hemp-containing supplements with an immune booster claim. “To further enhance the immune boosting effect, we added hemp seed oil (no THC) to our patented formulation. Hemp seed oil is rich in essential fatty acids (e.g., omega-6 and omega-3) and antioxidants that may help fight inflammation, cancer, diabetes, and heart disease,” Dr. Bobby Ghalili, co-founder and president of Cannaworx, stated in the news release. “Omega-3 is also thought to have a positive impact on the bowel microbiome as a prebiotic, providing further support to the immune system. The manufacturing process of the patented 44 amino acid fragment formulation is highly proprietary, protected, and would be nearly impossible to imitate.”

To view the full press release, visit http://ibn.fm/nqpvZ

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life-sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure-cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the biopharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and (ii) prepare higher-quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Pressure BioSciences Inc. PBIO | Leave a comment

MissionIRNewsBreaks – Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Enters Partnership with Sutesen to Expand Smart Immersive Education Classes

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) today announced its entry into a three-year partnership with smart education service provider, Sutesen Information Technology Ltd. (“Sutesen”), to expand Blue Hat’s Smart Immersive Education Classes, or “AR Immersive Classes” (“ARIC”), in Guangxi province, China. According to the update, the partnership aims to commercially launch ARIC in up to 1,000 Guangxi preschools in three years. “We believe the development of AR technology has great potential to change the way children interact with educational content, merging the real with the virtual for a truly immersive smart educational experience,” Blue Hat CEO Xiaodong Chen stated in the news release. “We are excited by the bright prospects of this wide-ranging partnership between Blue Hat and Sutesen, and we look forward to close co-operation in sharing resources such as channels, products, technology and content, as well as joint promotion of AR education.”

To view the full press release, visit http://ibn.fm/k06Fe

About Blue Hat

Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games and toys with mobile game features. The company’s interactive entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the company’s investor relations website at www.IR.BlueHatGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Blue Hat Interactive Entertainment Technology BHAT, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) Implements Changes as Part of Strategic and Operational Review of Business

Canopy Rivers (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, today announced a series of operational changes designed to optimize its organizational structure, streamline operations, and preserve and maximize cash-on-hand. According to the update, the company, as part of its strategic and operational review of the business, is implementing changes including a material reduction in the company’s operating cash outflows; a focus on generating positive cash flow; and a focus on maximizing returns on existing assets. In addition, the company today reaffirmed its intention, under its previously announced normal course issuer bid (the “NCIB”), to repurchase subordinated voting shares in accordance with its NCIB. “We believe that sharpening our focus on financial discipline, operational excellence, and opportunistic capital deployment on our investment pipeline will yield long-term results for shareholders,” Canopy Rivers’ CEO and President Narbe Alexandrian stated in the news release. “In addition, the strategic utilization of our NCIB could be an important tool to provide attractive returns to shareholders.”

To view the full press release, visit http://ibn.fm/KW3bT

About Canopy Rivers

Canopy Rivers is a venture capital firm specializing in cannabis. Its unique investment and operating platform is structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire portfolio. For more information, visit www.CanopyRivers.com.

NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://ibn.fm/CNPOF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Canopy Rivers Inc. CNPOF, MissionIRNewsBreaks | Leave a comment